MASI vs. ITGR, TMDX, LIVN, CNMD, RVMD, BPMC, JAZZ, ENSG, HQY, and EXEL
Should you be buying Masimo stock or one of its competitors? The main competitors of Masimo include Integer (ITGR), TransMedics Group (TMDX), LivaNova (LIVN), CONMED (CNMD), Revolution Medicines (RVMD), Blueprint Medicines (BPMC), Jazz Pharmaceuticals (JAZZ), The Ensign Group (ENSG), HealthEquity (HQY), and Exelixis (EXEL). These companies are all part of the "medical" sector.
Masimo (NASDAQ:MASI) and Integer (NYSE:ITGR) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.
86.0% of Masimo shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 9.7% of Masimo shares are owned by insiders. Comparatively, 2.0% of Integer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Integer had 2 more articles in the media than Masimo. MarketBeat recorded 8 mentions for Integer and 6 mentions for Masimo. Masimo's average media sentiment score of 1.32 beat Integer's score of 1.05 indicating that Masimo is being referred to more favorably in the media.
Integer has a net margin of 6.01% compared to Masimo's net margin of 4.01%. Masimo's return on equity of 13.26% beat Integer's return on equity.
Integer has lower revenue, but higher earnings than Masimo. Integer is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.
Masimo received 76 more outperform votes than Integer when rated by MarketBeat users. Likewise, 63.84% of users gave Masimo an outperform vote while only 63.41% of users gave Integer an outperform vote.
Masimo has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Integer has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Masimo presently has a consensus price target of $138.71, suggesting a potential upside of 9.07%. Integer has a consensus price target of $128.00, suggesting a potential upside of 5.49%. Given Masimo's higher possible upside, analysts clearly believe Masimo is more favorable than Integer.
Summary
Masimo beats Integer on 10 of the 18 factors compared between the two stocks.
Get Masimo News Delivered to You Automatically
Sign up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
